GATA1 and neoplasm: The results of the randomized, placebo-controlled, multicenter trial in women undergoing breast cancer surgery (NCT00502684), with 38 patients treated from pre-operative day 3 to post-operative day 2, showed a decrease in tumor cell migration capacity and subsequent metastasis by reducing the epithelial to mesenchymal transition (EMT), premetastatic/proinflammatory transcription factors, such as GATA-1 and the early-growth response-3/EGR3, tumor-infiltrating monocytes, and inflammatory cytokines, such as IL-6 [79,80,81] (Table S3).